493 related articles for article (PubMed ID: 20030477)
41. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
42. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients.
Cies JJ; Varlotta L
Pediatr Pulmonol; 2013 Dec; 48(12):1190-4. PubMed ID: 23281228
[TBL] [Abstract][Full Text] [Related]
43. Single daily dosing of aminoglycosides.
Preston SL; Briceland LL
Pharmacotherapy; 1995; 15(3):297-316. PubMed ID: 7667165
[TBL] [Abstract][Full Text] [Related]
44. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
45. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
46. Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia.
Mercer JM; Neyens RR
Pharmacotherapy; 2010 Jul; 30(7):654-60. PubMed ID: 20575630
[TBL] [Abstract][Full Text] [Related]
47. Management of aminoglycosides in the intensive care unit.
Radigan EA; Gilchrist NA; Miller MA
J Intensive Care Med; 2010; 25(6):327-42. PubMed ID: 20837630
[TBL] [Abstract][Full Text] [Related]
48. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices.
Heintz BH; Thompson GR; Dager WE
Ann Pharmacother; 2011 Nov; 45(11):1338-45. PubMed ID: 22010003
[TBL] [Abstract][Full Text] [Related]
49. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients.
Koo J; Tight R; Rajkumar V; Hawa Z
Am J Med; 1996 Aug; 101(2):177-83. PubMed ID: 8757358
[TBL] [Abstract][Full Text] [Related]
50. Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation.
Sung L; Dupuis LL; Bliss B; Taddio A; Abdolell M; Allen U; Rolland M; Tong A; Taylor T; Doyle J
J Natl Cancer Inst; 2003 Dec; 95(24):1869-77. PubMed ID: 14679156
[TBL] [Abstract][Full Text] [Related]
51. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
Phillips JA; Bell SC
Intern Med J; 2001; 31(1):23-6. PubMed ID: 11478352
[TBL] [Abstract][Full Text] [Related]
52. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
[No Abstract] [Full Text] [Related]
53. Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis.
DeGrado JR; Cios D; Greenwood BC; Kubiak DW; Szumita PM
J Chemother; 2014 Apr; 26(2):101-4. PubMed ID: 24090527
[TBL] [Abstract][Full Text] [Related]
54. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.
O'Donnell EP; Scarsi KK; Scheetz MH; Postelnick MJ; Cullina J; Jain M
Int J Antimicrob Agents; 2010 Jul; 36(1):94-5. PubMed ID: 20382508
[No Abstract] [Full Text] [Related]
55. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients.
Mareville J; Gay J; Cliquennois E; Herbaux C; Pasquier F; Allorge D; Blondiaux N; Berthon C; Alfandari S
Scand J Infect Dis; 2012 May; 44(5):398-401. PubMed ID: 22235869
[TBL] [Abstract][Full Text] [Related]
56. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
[No Abstract] [Full Text] [Related]
57. Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit.
Ohler KH; Menke JA; Fuller L
Am J Perinatol; 2000; 17(6):285-90. PubMed ID: 11144309
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
Beringer PM; Vinks AA; Jelliffe RW; Shapiro BJ
Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
[TBL] [Abstract][Full Text] [Related]
59. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.
Pai MP; Rodvold KA
Diagn Microbiol Infect Dis; 2014 Feb; 78(2):178-87. PubMed ID: 24268292
[TBL] [Abstract][Full Text] [Related]
60. Aminoglycosides use in patients over 75 years old.
Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
